ASCIA Guidelines – Intravenous Immunoglobulin Replacement Therapy Infusion Rates and Adverse Reactions Guide

These Guidelines are currently under review and are expected to be finalised by mid December 2024. 

In the meantime, we suggest that clinicians follow the information from the suppliers of each IVIg product or refer to the RCH VIC IVIg Guideline.

Content updated December 2024